The Evolving and Emerging Role of Plasma Biomarkers in Diagnosing and Monitoring Alzheimer Disease
April 5th 2025Inge Verberk, PhD, a research associate at the Amsterdam University Medical Center, sat down at AD/PD 2025 to discuss changes in Alzheimer trials, the emergence of plasma biomarkers, and deciphering which biomarkers are of utmost importance.
Novel IVD Tool for Rapid APOE Genotyping May Aid in Alzheimer Disease Risk Stratification
April 4th 2025A recent poster presentation at the 2025 AD/PD conference revealed that a novel assay could provide absolute allelic discrimination for APOE genotyping, supporting precision medicine in AD treatment.
Sweden Analysis Reveals Key Lifestyle and Socioeconomic Factors Driving Cognitive Decline
April 4th 2025An analysis of the Gothenburg Mild Cognitive Impairment Study presented at the 2025 AD/PD Conference reported that lifestyle and socioeconomic factors could significantly influence the risk of developing cognitive diseases.
Beyond CSF: Quanterix’s Simoa Platform Brings Blood-Based Biomarkers to the Forefront
April 3rd 2025Mark Roskey, PhD, chief scientific officer at Quanterix, provided clinical insight on the function of the company’s Simoa technology and the incorporation of various biomarkers to aid in the diagnosis of Alzheimer disease.
Assessing Investigational CT1812’s Impact on Tau, Amyloid, and Neurodegeneration: Mary Hamby, PhD
April 3rd 2025The vice president of research at Cognition Therapeutics gave clinical insight on several new analyses covering CT1812, an orally delivered small molecule oligomer antagonist, in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]
Patient-Informed Phase 2 ATLANTIS Study Tests Selective D1PAM Agent Glovadalen for Parkinson Disease
April 3rd 2025Presented at the 2025 AD/PD Conference, the study incorporates patient engagement in its design and implementation, focusing on optimizing study accessibility, reducing burden, and evaluating glovadalen’s potential as an adjunctive treatment for PD.
Alzheimer Biomarkers pTau217 and pTau181 Show High Group-Level Correlation With Trial End Points
April 2nd 2025Investigators at AD/PD 2025 presented new data showing that changes in plasma p-tau217 and p-tau181 closely correlate with clinical outcomes in anti-amyloid therapy trials for Alzheimer disease.
NeuroVoices: Cynthia Lemere, PhD, on Exploring the Role of Complement in ARIA and CAA
April 2nd 2025The professor of neurology at Brigham and Women’s Hospital gave clinical insights on the therapeutic potential of targeting compliment as a way to mitigate risk for amyloid-related imaging abnormalities from antiamyloid therapies.
Exploring Multimodal Approaches to Neural Regeneration: Kuldip Dave, PhD
March 31st 2025The senior vice president of research at The ALS Association talked about a multidisciplinary session presented at the 2025 MDA Conference that highlighted diverse strategies for neural repair, from pharmacological targets to noninvasive brain stimulation. [WATCH TIME: 6 minutes]
Insights into OPMD and Advancements in Genetic Research: Matthew Wicklund, MD
March 31st 2025The professor of neurology at the University of Texas Health Science Center San Antonio provided clinical insights on the genetic basis of oculopharyngeal muscular dystrophy, as well as the primary challenges in diagnosing and treating the condition. [WATCH TIME: 5 minutes]
The Urgency of Funding and Equity in Neuromuscular Research and Care: Robert Califf, MD
March 27th 2025The former FDA commissioner spoke on the need for policy and funding efforts for neuromuscular disorders, the stress on the clinical care system, and the need to acknowledge healthcare inequities. [WATCH TIME: 4 minutes]